5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy-Reference-Cited by-同舟云学术

5-Substituted-N-pyridazinylbenzamides as potent and selective LRRK2 inhibitors: Improved brain unbound fraction enables efficacy

Published:2019-01 Issue:2 Volume:29 Page:212-215
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Ding Xiao,Stasi Luigi Piero,Dai Xuedong,Long Kai,Peng Cheng,Zhao Baowei,Wang Hailong,Sun Changhui,Hu Huan,Wan Zehong,Jandu Karamjit S.,Philps Oliver J.,Chen Yan,Wang Lizhen,Liu Qian,Edge Colin^ORCID,Li Yi,Dong Kelly,Guan Xiaoming,Tattersall F. David,Reith Alastair D.,Ren Feng

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference25 articles.

1. Parkinson disease

2. The prevalence of Parkinson's disease: A systematic review and meta-analysis

3. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

4. Current and experimental treatments of Parkinson disease: A guide for neuroscientists

5. Disease-modifying strategies for Parkinson's disease

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson’s disease;Bioorganic Chemistry;2023-12

2. Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives;European Journal of Medicinal Chemistry;2023-08

3. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson’s Disease;Journal of Medicinal Chemistry;2023-02-09

4. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease;J MED CHEM;2023

5. Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2;International Journal of Molecular Sciences;2022-10-24